168 related articles for article (PubMed ID: 34572765)
41. Clinicopathological characteristics of endometrial carcinomas according to DNA mismatch repair protein status.
de Freitas D; Aguiar FN; Anton C; de Almeida DC; Bacchi CE; Carvalho JP; Carvalho FM
Heliyon; 2023 Jun; 9(6):e17495. PubMed ID: 37408903
[TBL] [Abstract][Full Text] [Related]
42. Mutation-specific Mismatch Repair-deficient Benign Endometrial Glands in Endometrial Biopsies and Curettings Are a Biomarker of Lynch Syndrome and Associate With Endometrial Carcinoma Development.
Hegazy S; Brand RE; Dudley B; Karloski E; Lesnock JL; Elishaev E; Pai RK
Am J Surg Pathol; 2023 Jul; 47(7):835-843. PubMed ID: 37226842
[TBL] [Abstract][Full Text] [Related]
43. Teenage-Onset Colorectal Cancers in a Digenic Cancer Predisposition Syndrome Provide Clues for the Interaction between Mismatch Repair and Polymerase δ Proofreading Deficiency in Tumorigenesis.
Schamschula E; Kinzel M; Wernstedt A; Oberhuber K; Gottschling H; Schnaiter S; Friedrichs N; Merkelbach-Bruse S; Zschocke J; Gallon R; Wimmer K
Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291559
[TBL] [Abstract][Full Text] [Related]
44. Lynch syndrome pre-screening and comprehensive characterization in a multi-center large cohort of Chinese patients with colorectal cancer.
Li Y; Fan L; Zheng J; Nie X; Sun Y; Feng Q; Lian S; Bai W; Cai W; Yang Y; Su B; Xi Y; Lin D
Cancer Biol Med; 2022 Jun; 19(8):1235-48. PubMed ID: 35638907
[TBL] [Abstract][Full Text] [Related]
45. Targeted next-generation sequencing of 22 mismatch repair genes identifies Lynch syndrome families.
Talseth-Palmer BA; Bauer DC; Sjursen W; Evans TJ; McPhillips M; Proietto A; Otton G; Spigelman AD; Scott RJ
Cancer Med; 2016 May; 5(5):929-41. PubMed ID: 26811195
[TBL] [Abstract][Full Text] [Related]
46. Lynch Syndrome Screening of Women with Endometrial Cancer: Feasibility and Outcomes in a Community Program.
Turashvili G; Colgan T; McLachlin M; Lin H; Gharbharan R
J Obstet Gynaecol Can; 2022 Feb; 44(2):142-147. PubMed ID: 34656766
[TBL] [Abstract][Full Text] [Related]
47. Implications of Hereditary Origin on the Immune Phenotype of Mismatch Repair-Deficient Cancers: Systematic Literature Review.
Bohaumilitzky L; von Knebel Doeberitz M; Kloor M; Ahadova A
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32512823
[TBL] [Abstract][Full Text] [Related]
48. Usefulness of immunohistochemistry for mismatch repair protein and microsatellite instability examination in adenocarcinoma and background endometrium of sporadic endometrial cancer cases.
Saeki H; Hlaing MT; Horimoto Y; Kajino K; Ohtsuji N; Fujino K; Terao Y; Hino O
J Obstet Gynaecol Res; 2019 Oct; 45(10):2037-2042. PubMed ID: 31307113
[TBL] [Abstract][Full Text] [Related]
49. Mismatch Repair Universal Screening of Endometrial Cancers (MUSE) in a Canadian Cohort.
Lawrence J; Richer L; Arseneau J; Zeng X; Chong G; Weber E; Foulkes W; Palma L
Curr Oncol; 2021 Jan; 28(1):509-522. PubMed ID: 33467402
[TBL] [Abstract][Full Text] [Related]
50. Unexplained mismatch repair deficiency: Case closed.
Eikenboom EL; Moen S; van Leeuwen L; Geurts-Giele WRR; Tops CMJ; van Ham TJ; Dinjens WNM; Dubbink HJ; Spaander MCW; Wagner A
HGG Adv; 2023 Jan; 4(1):100167. PubMed ID: 36624813
[TBL] [Abstract][Full Text] [Related]
51. Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies.
Vyas M; Firat C; Hechtman JF; Weiser MR; Yaeger R; Vanderbilt C; Benhamida JK; Keshinro A; Zhang L; Ntiamoah P; Gonzalez M; Andrade R; El Dika I; Markowitz AJ; Smith JJ; Garcia-Aguilar J; Vakiani E; Klimstra DS; Stadler ZK; Shia J
Fam Cancer; 2021 Jul; 20(3):201-213. PubMed ID: 33033905
[TBL] [Abstract][Full Text] [Related]
52. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
[TBL] [Abstract][Full Text] [Related]
53. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
[TBL] [Abstract][Full Text] [Related]
54. Interpretation of somatic POLE mutations in endometrial carcinoma.
León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
[TBL] [Abstract][Full Text] [Related]
55. Rare germline mutation and MSH2-&MSH6 + expression in a double primary carcinoma of colorectal carcinoma and endometrial carcinoma: a case report.
Zhang T; Huang X; Liu W; Ling X; Su Z; Huang M; Che S
Diagn Pathol; 2024 Jan; 19(1):25. PubMed ID: 38297350
[TBL] [Abstract][Full Text] [Related]
56. DNA mismatch repair-deficient non-neoplastic endometrial glands are common in Lynch syndrome patients and are present at a higher density than in the colon.
Hegazy S; Brand RE; Dudley B; Karloski E; Bhargava R; Elishaev E; Pai RK
Histopathology; 2021 Oct; 79(4):573-583. PubMed ID: 33847404
[TBL] [Abstract][Full Text] [Related]
57. Differences in the molecular profile of endometrial cancers from British White and British South Asian women.
Polymeros K; Guttery DS; Hew R; Bishop R; Stannard E; Macip S; Symonds P; Moss EL
PLoS One; 2020; 15(6):e0233900. PubMed ID: 32520976
[TBL] [Abstract][Full Text] [Related]
58. Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers.
Georgeson P; Pope BJ; Rosty C; Clendenning M; Mahmood K; Joo JE; Walker R; Hutchinson RA; Preston S; Como J; Joseland S; Win AK; Macrae FA; Hopper JL; Mouradov D; Gibbs P; Sieber OM; O'Sullivan DE; Brenner DR; Gallinger S; Jenkins MA; Winship IM; Buchanan DD
Gut; 2021 Nov; 70(11):2138-2149. PubMed ID: 33414168
[TBL] [Abstract][Full Text] [Related]
59. The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells.
Bommi PV; Bowen CM; Reyes-Uribe L; Wu W; Katayama H; Rocha P; Parra ER; Francisco-Cruz A; Ozcan Z; Tosti E; Willis JA; Wu H; Taggart MW; Burks JK; Lynch PM; Edelmann W; Scheet PA; Wistuba II; Sinha KM; Hanash SM; Vilar E
Cancer Res; 2021 May; 81(10):2760-2773. PubMed ID: 34003775
[TBL] [Abstract][Full Text] [Related]
60. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.
Chang K; Taggart MW; Reyes-Uribe L; Borras E; Riquelme E; Barnett RM; Leoni G; San Lucas FA; Catanese MT; Mori F; Diodoro MG; You YN; Hawk ET; Roszik J; Scheet P; Kopetz S; Nicosia A; Scarselli E; Lynch PM; McAllister F; Vilar E
JAMA Oncol; 2018 Aug; 4(8):1085-1092. PubMed ID: 29710228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
